Parminder Minhas, MD
Pulmonary Disease · Oklahoma City, OKNPI 1932581592
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,755 of the $5,565 with a category attached, or 67.5%. It is spread thinly across 30 manufacturers, the largest accounting for just 21.3%. Reporting peaked in 2023 at $2,564 and has fallen 91.1% since, to $227 in 2025.
Across 177 payments — averaging $31.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$1K
- Intuitive Surgical$955
- Insmed, Inc.$595
- AstraZeneca$526
- Boehringer Ingelheim$524
- GSK$301
- plus $1K from 24 others
What the payments were for
- Travel & lodging$1,79732%
- Food & beverage$3,75567%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pulmonx Corporation | 8 | $1,185 |
| Intuitive Surgical | 7 | $955 |
| Insmed, Inc. | 27 | $595 |
| AstraZeneca(2 entities) | 28 | $526 |
| Boehringer Ingelheim | 21 | $524 |
| GSK | 17 | $301 |
| Novartis | 8 | $182 |
| Gilead | 6 | $133 |
| Actelion Pharmaceuticals US, Inc. | 5 | $127 |
| Baxter Healthcare | 5 | $120 |
| Sanofi | 5 | $109 |
| Amgen | 4 | $83 |
| Genentech USA, Inc. | 3 | $64 |
| Jazz Pharmaceuticals Inc. | 3 | $60 |
| La Jolla Pharmaceutical Company | 3 | $57 |
| United Therapeutics Corporation | 3 | $55 |
| Grifols USA, LLC | 2 | $52 |
| Mylan Specialty L.p. | 3 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Fisher & Paykel Healthcare Inc | 2 | $43 |
| Vifor Pharma, Inc. | 2 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Philips North America LLC | 2 | $31 |
| Merck | 1 | $31 |
| Pfizer | 2 | $31 |
| Portola Pharmaceuticals, LLC | 1 | $25 |
| Johnson & Johnson | 1 | $20 |
| Bayer | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,565 in reported general payments places this provider in the 70th percentile of 133 pulmonary disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 210 | $176,447 |
| OfevNintedanib Esylate | 11 | $142,574 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $15,364 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $9,040 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,268 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $2,843 |
| Ventolin HfaAlbuterol Sulfate | 15 | $1,518 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 72 | $1,404 |
| Montelukast Sodium | 92 | $1,223 |
| Wixela InhubFluticasone Propion/Salmeterol | 17 | $1,109 |
| Azelastine Hcl | 13 | $361 |
| Fluticasone Propionate | 16 | $251 |
| Gabapentin | 15 | $108 |
| Prednisone | 28 | $83 |
| Levofloxacin | 11 | $47 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $301 | $200,851251 claims |
| Boehringer IngelheimOfev, Stiolto Respimat | $524 | $147,84122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 133 pulmonary disease providers in Oklahoma.
Other pulmonary disease in Oklahoma City
- John KingreyOklahoma City$332K
- Fawad ChaudryOklahoma City$80K
- Maroun TawkOklahoma City$62K
- Nathaniel MoultonOklahoma City$28K
- Syed NaqviOklahoma City$15K
- Tarek DernaikaOklahoma City$12K
- Shoab NazirOklahoma City$11K
- Mark GodishOklahoma City$11K
- Mazen ZouwayhedOklahoma City$10K
- Shoaib AhmadOklahoma City$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.